ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Check out the list of late-breaking clinical trials being presented as orals and posters.

Kidney Week 2023: Call for Late-Breaking Clinical Trials

ASN will accept Late-Breaking Clinical Trial (LBCT) submissions electronically from July 19, 2023, through September 6, 2023 (2:00 p.m. EDT). Submissions should discuss randomized trials (Phase 2, 3, 4) that will have significant impact on clinical practice. Please allow adequate time before September 6 for ALL authors to create an ASN User Login, if they do not already have one, and to provide 24 months of FULL disclosures.

Table of Contents


Clinical trials "are designed to add to medical knowledge related to the treatment, diagnosis, and prevention of diseases or conditions. Some common reasons for conducting clinical studies include: Evaluating one or more interventions…for treating a disease, syndrome, or condition…Finding ways to prevent the initial development or recurrence of a disease or condition…Evaluating one or more interventions aimed at identifying or diagnosing a particular disease or condition…Examining methods for identifying a condition or risk factors for that condition…Exploring and measuring ways to improve the comfort and quality of life of people with a chronic illness through supportive care" (

Your LBCT submission MUST meet the following criteria for ASN consideration:

  • ASN considers submissions for Phase 2, 3, and 4 trials only.
  • Your data has not been and will not be presented at a U.S. or international meeting before presentation at Kidney Week.
  • Your data has not been and will not be published in any form (including preprint servers) before presentation at Kidney Week.
  • ASN has adopted the ICMJE criteria: "authorship be based on...1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved." For your LBCT submission:
    • ALL authors have been added to the abstract at time of submission.
    • ALL authors have submitted their own disclosures.
    • ALL authors have full access to all study data and statistical analyses of the data. If that is not the case, the abstract may be rejected or retracted.
  • The Submitter has the authority to submit the LBCT and transfer copyright on behalf of the co-authors and company sponsors.
  • All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.
  • Submit as much data as possible. The LBCT review committee will make decisions and assignments based on the information submitted.
  • Do not submit multiple abstracts on the same trial - only one abstract submission per trial.

Submission Details

  1. All LBCT abstracts must be submitted electronically through the ASN abstract submission site by September 6, 2023, 2:00 p.m. EDT for consideration.
  2. ALL authors must have an ASN User Login and provide 24 months of FULL disclosures BEFORE they can be added to an abstract. ALL authors must submit their own disclosures. (Click here for the ASN Conflict of Interest and Disclosure Policy.)
    • Submitter/Submitting Author: This individual serves as the secondary point of contact with ASN regarding the submission. The Submitter is not required to be a contributing author (e.g., administrative assistant or student working with the authors) but must have an ASN User Login with current contact information for submission.
    • Presenting (First) Author: This individual is the first author listed in the submission and has the primary responsibility for communications with ASN. The Presenting Author is responsible for ensuring that ALL co-authors approve the submission, publication, and potential presentation. The Presenting Author is responsible for ensuring that ALL co-authors who participated in the study and meet the criteria for authorship are listed on the abstract when it is submitted to ASN. The Presenting Author will give the oral or poster presentation, if the submission is accepted, and should feel comfortable presenting and answering questions in English. Please note that the submission system recognizes the first author as the Presenting Author; these roles cannot be differentiated in the system or in the Kidney Week program. The Presenting Author must be the first author listed.
    • Co-Authors: The co-authors will be listed in the order provided during submission.
  3. An abstract submission may contain a maximum of 2,500 characters. The total character count includes characters and spaces in the following fields: Title, Body, Figures (up to 2), Table (up to 1), Author Names (as they appear once added on Step 4 of the submission process). Figure count is determined by image height but will not exceed 560 characters. Because image height cannot be calculated manually, we recommend uploading, editing, and replacing figures in the submission until an acceptable quality : character ratio is reached. Table count is 50 characters per row. For complex tables and in situations where control over formatting is desired, we recommend uploading the table as a figure. Author Institutions do not count towards the character count.
  4. The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. An abstract may be submitted and paid for, then returned to draft, edited, and resubmitted for no additional fee by September 6, 2023, at 2:00 p.m. EDT.
  5. There is no limit to the number of abstracts that an individual may submit. However, there is a $95 nonrefundable processing fee per submission. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
  6. Upon abstract submission, ALL authors agree to all copyright transfer terms and the ASN embargo policy.
  7. Changes: It is important that the lead author checks the abstract data carefully before submission. For submitted abstracts needing changes through September 6, 2023, the contact author can make changes directly in the abstract submission site. After September 6, please email for minimal change requests which will be handled on a case-by-case basis; ASN may not be able to accommodate all requests. Minimal changes include author additions (if total character limit permits) and typos, but NOT replacements of text, table, and figures.
  8. Withdrawals: The lead author can request abstract withdrawal through September 30, 2023, by emailing Please note the abstract number in the email subject line and the lead author's name in the email body. The $95 processing fee is nonrefundable. After September 30, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.

Assignment, Notification, and Presentation

All abstract submissions are peer reviewed by the LBCT review committee, and authors' names and institutions are blinded during the review process. LBCT submissions can be (1) accepted as an oral abstract, (2) accepted as a poster, or (3) rejected. There is no publication-only option for LBCT submissions.

Accepted abstracts will be assigned to one of the following:

  • High-Impact Clinical Trials Oral Session(s): This session for late-breaking clinical trials will be held in-person in Philadelphia, PA on Friday, November 3, 10:30 a.m. - 12:30 p.m. EDT. A second session may be added on Saturday, November 4, 10:30 a.m. - 12:30 p.m. EDT. The session(s) will be recorded for later viewing.
  • Late-Breaking Posters: Posters will be presented in-person in Philadelphia, PA in the exhibit hall on Thursday, November 2, 10:00 a.m. - 12:00 p.m. EDT. If accepted for poster presentation, the Presenting (First) Author or a co-author must be available at the poster board at 10:00 a.m. - 12:00 p.m. EDT for presentation and discussion. Poster presenters are encouraged to submit an ePoster to complement their printed poster. ePosters will be available for viewing online starting Thursday, November 2, 10:00 a.m. EDT.

It is the responsibility of the Presenting (First) Author to (1) share the notifications with their co-authors, (2) affirm that no updates are needed to co-author disclosures; and (3) immediately notify ASN if any updates are needed to co-author disclosures. If you are the Presenting Author and have not received your notification by September 30, please email and note the abstract number in the email subject line and the Presenting Author's name in the email body.

The Presenting Authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and travel to Philadelphia, PA to present in-person.

ASN reserves the right to withdraw any submission for any reason in its discretion.

Confidential Advanced Access

All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.